摘要
淋巴瘤是一种以淋巴细胞为主要来源的高度异质性肿瘤。^(18)F-FDG PET/CT通过对肿瘤细胞状态和肿瘤微环境变化的异质性FDG摄取进行评估,被广泛用于嗜FDG淋巴瘤分期、再分期及治疗反应评估。但常规PET参数在全面评估肿瘤异质性方面存在不足。本文总结PET/CT在淋巴瘤诊断、分期、治疗及预后评估中的作用,并探讨PET/CT未来发展方向,包括新PET参数的探索、新试剂的开发和人工智能的融合,这些领域在淋巴瘤检测、异质性量化、鉴别、中期疗效评估和预测预后等方面取得了重大突破。
Lymphoma,a highly heterogeneous tumor primarily derived from lymphocytes,can be effectively staged,restaged,and assessed for treatment response using ^(18)F-FDG PET/CT.This imaging technique evaluates the heterogeneous FDG uptake in tumor cells and changes in the tumor microenvironment.However,conventional PET parameters alone are insufficient for a comprehensive assessment of tumor heterogeneity.This article provides an overview of the role of PET/CT in diagnosing,staging,treating,and assessing the prognosis of lymphoma.Furthermore,it explores the future development direction of PET/CT,including the investigation of new PET parameters,the development of novel agents,and the integration of artificial intelligence.Significant advancements have been made in tumor detection,quantification of heterogeneity,identification,midterm efficacy evaluation,and prognosis prediction.
作者
詹华英
李伟龙
于丽硕
刘志翔
ZHAN Huaying;LI Weilong;YU Lishuo;LIU Zhixiang(School of Medical imaging,Weifang Medical University,Weifang 261000,China;Department of Nuclear Medicine,Yantai Yuhuangding Hospital,Yantai 264000,China;Department of Nuclear Medicine,the Affiliated Hospital of Weifang Medical University,Weifang 261000,China)
出处
《分子影像学杂志》
2024年第2期220-224,共5页
Journal of Molecular Imaging
基金
山东省医药卫生科技发展计划项目(2017WS876)。
